---
document_datetime: 2025-12-29 12:25:26
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/rubraca.html
document_name: rubraca.html
version: success
processing_time: 0.1356541
conversion_datetime: 2025-12-31 02:46:03.412152
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Rubraca

[RSS](/en/individual-human-medicine.xml/65954)

##### Authorised

This medicine is authorised for use in the European Union

rucaparib Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Rubraca](#news-on)
- [More information on Rubraca](#more-information-on-rubraca-570)
- [More information on Rubraca](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Rubraca is a cancer medicine for treating high-grade cancers of the ovary, fallopian tubes (the tubes connecting the ovaries to the uterus) and the peritoneum (the membrane lining the abdomen).

It is used as maintenance treatment in patients newly diagnosed with advanced cancer or in patients whose cancer has come back, and in whom the cancer has cleared (partially or completely) after treatment with platinum-based chemotherapy. Rubraca contains the active substance rucaparib.

Expand section

Collapse section

## How is Rubraca used?

Rubraca can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the treatment of cancer.

Rubraca is available as tablets to be taken twice a day. Treatment should continue until the cancer progresses or the patient has unacceptable side effects, and no longer than 2 years for patients newly diagnosed with advanced cancer. Treatment with Rubraca should be started no later than 8 weeks after the patient has finished their treatment with platinum-based chemotherapy.

For more information about using Rubraca, see the package leaflet or contact your doctor or pharmacist.

## How does Rubraca work?

The active substance in Rubraca, rucaparib, blocks the activity of a family of proteins called poly(ADP-ribose) polymerases (PARPs) that help to repair damaged DNA in cells (both normal and cancer cells). When PARP proteins are blocked, the damaged DNA in the cancer cells cannot be repaired and the cells die as a result.

## What benefits of Rubraca have been shown in studies?

Rubraca was investigated in a main study of 564 patients with recurring ovarian cancer which had cleared (partially or completely) after treatment with platinum-based chemotherapy. Patients given Rubraca lived for 11 months without the disease coming back or getting worse compared with 5 months in patients given placebo (a dummy treatment).

Another study looked at 538 patients with newly diagnosed advanced ovarian cancer which had cleared (partially or completely) after treatment with platinum-based chemotherapy. Patients given Rubraca lived for 20 months without the disease coming back or getting worse compared with 9 months in patients given placebo.

## What are the risks associated with Rubraca?

For the full list of side effects and restrictions with Rubraca, see the package leaflet.

The most common side effects with Rubraca (which may affect more than 1 in 5 people) include tiredness or weakness, nausea (feeling sick), vomiting, anaemia (low red blood cell counts), abdominal pain (belly ache), dysgeusia (taste disturbances), increased levels of liver enzymes in the blood (which may indicate liver damage), decreased appetite, diarrhoea, neutropenia (low levels of neutrophils, a type of white blood cell that fights infection) and thrombocytopenia (low levels of platelets).

Women must not breastfeed during treatment with Rubraca and for at least 2 weeks after treatment.

## Why is Rubraca authorised in the EU?

Rubraca has been shown to delay worsening or return of the disease in patients whose cancer had cleared partially or completely after treatment with platinum-based chemotherapy. Regarding safety, side effects occur frequently but are generally not serious and are manageable with appropriate treatment. In addition, fewer liver and blood-related problems occur with Rubraca than with other existing treatments for these patients.

The European Medicines Agency decided that Rubraca's benefits are greater than its risks and it can be authorised for use in the EU.

Rubraca was originally given 'conditional authorisation' because there was more evidence to come about the use of Rubraca outside maintenance treatment of patients. This use has since been restricted 1 . The authorisation has therefore been switched from a conditional to a standard marketing authorisation.

1 Following a [review carried out in 2022](https://www.ema.europa.eu/en/news/ema-recommends-restricting-use-cancer-medicine-rubraca) , the use of Rubraca in patients whose cancer has returned or worsened after two treatments with platinum-based chemotherapy is no longer recommended.

## What measures are being taken to ensure the safe and effective use of Rubraca?

The company that markets Rubraca will provide final results to confirm the effectiveness of Rubraca as a maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer has cleared (partially or completely) after treatment with platinum-based chemotherapy.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rubraca have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Rubraca are continuously monitored. Side effects reported with Rubraca are carefully evaluated and any necessary action taken to protect patients.

## Other information about Rubraca

Rubraca received a conditional marketing authorisation valid throughout the EU on 24 May 2018. This was switched to a standard marketing authorisation on 9 November 2022.

Rubraca : EPAR - Medicine overview

Reference Number: EMA/469708/2023

English (EN) (105.14 KB - PDF)

**First published:** 31/05/2018

**Last updated:** 30/11/2023

[View](/en/documents/overview/rubraca-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-660)

български (BG) (129.4 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

30/11/2023

[View](/bg/documents/overview/rubraca-epar-medicine-overview_bg.pdf)

español (ES) (103.22 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

30/11/2023

[View](/es/documents/overview/rubraca-epar-medicine-overview_es.pdf)

čeština (CS) (126.82 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

30/11/2023

[View](/cs/documents/overview/rubraca-epar-medicine-overview_cs.pdf)

dansk (DA) (104.15 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

30/11/2023

[View](/da/documents/overview/rubraca-epar-medicine-overview_da.pdf)

Deutsch (DE) (106.77 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

30/11/2023

[View](/de/documents/overview/rubraca-epar-medicine-overview_de.pdf)

eesti keel (ET) (100.58 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

30/11/2023

[View](/et/documents/overview/rubraca-epar-medicine-overview_et.pdf)

ελληνικά (EL) (129.44 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

30/11/2023

[View](/el/documents/overview/rubraca-epar-medicine-overview_el.pdf)

français (FR) (104.25 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

30/11/2023

[View](/fr/documents/overview/rubraca-epar-medicine-overview_fr.pdf)

hrvatski (HR) (123.55 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

30/11/2023

[View](/hr/documents/overview/rubraca-epar-medicine-overview_hr.pdf)

italiano (IT) (102.2 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

30/11/2023

[View](/it/documents/overview/rubraca-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (132.88 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

30/11/2023

[View](/lv/documents/overview/rubraca-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (125.27 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

30/11/2023

[View](/lt/documents/overview/rubraca-epar-medicine-overview_lt.pdf)

magyar (HU) (125.97 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

30/11/2023

[View](/hu/documents/overview/rubraca-epar-medicine-overview_hu.pdf)

Malti (MT) (127.68 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

30/11/2023

[View](/mt/documents/overview/rubraca-epar-medicine-overview_mt.pdf)

Nederlands (NL) (103.76 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

30/11/2023

[View](/nl/documents/overview/rubraca-epar-medicine-overview_nl.pdf)

polski (PL) (128.31 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

30/11/2023

[View](/pl/documents/overview/rubraca-epar-medicine-overview_pl.pdf)

português (PT) (104.1 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

30/11/2023

[View](/pt/documents/overview/rubraca-epar-medicine-overview_pt.pdf)

română (RO) (122.58 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

30/11/2023

[View](/ro/documents/overview/rubraca-epar-medicine-overview_ro.pdf)

slovenčina (SK) (126.11 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

30/11/2023

[View](/sk/documents/overview/rubraca-epar-medicine-overview_sk.pdf)

slovenščina (SL) (124.13 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

30/11/2023

[View](/sl/documents/overview/rubraca-epar-medicine-overview_sl.pdf)

Suomi (FI) (101.05 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

30/11/2023

[View](/fi/documents/overview/rubraca-epar-medicine-overview_fi.pdf)

svenska (SV) (102.46 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

30/11/2023

[View](/sv/documents/overview/rubraca-epar-medicine-overview_sv.pdf)

Rubraca : EPAR - Risk management plan

English (EN) (1.2 MB - PDF)

**First published:** 19/02/2019

**Last updated:** 30/11/2023

[View](/en/documents/rmp/rubraca-epar-risk-management-plan_en.pdf)

## Product information

Rubraca : EPAR - Product Information

English (EN) (564.45 KB - PDF)

**First published:** 31/05/2018

**Last updated:** 27/11/2025

[View](/en/documents/product-information/rubraca-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-950)

български (BG) (690.5 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/bg/documents/product-information/rubraca-epar-product-information_bg.pdf)

español (ES) (626.79 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/es/documents/product-information/rubraca-epar-product-information_es.pdf)

čeština (CS) (606.69 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/cs/documents/product-information/rubraca-epar-product-information_cs.pdf)

dansk (DA) (607.54 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/da/documents/product-information/rubraca-epar-product-information_da.pdf)

Deutsch (DE) (642.04 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/de/documents/product-information/rubraca-epar-product-information_de.pdf)

eesti keel (ET) (635.46 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/et/documents/product-information/rubraca-epar-product-information_et.pdf)

ελληνικά (EL) (850.22 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/el/documents/product-information/rubraca-epar-product-information_el.pdf)

français (FR) (636.37 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/fr/documents/product-information/rubraca-epar-product-information_fr.pdf)

hrvatski (HR) (711.65 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/hr/documents/product-information/rubraca-epar-product-information_hr.pdf)

íslenska (IS) (684.31 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/is/documents/product-information/rubraca-epar-product-information_is.pdf)

italiano (IT) (646.63 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/it/documents/product-information/rubraca-epar-product-information_it.pdf)

latviešu valoda (LV) (665.56 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/lv/documents/product-information/rubraca-epar-product-information_lv.pdf)

lietuvių kalba (LT) (610.21 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/lt/documents/product-information/rubraca-epar-product-information_lt.pdf)

magyar (HU) (670.08 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/hu/documents/product-information/rubraca-epar-product-information_hu.pdf)

Malti (MT) (744.41 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/mt/documents/product-information/rubraca-epar-product-information_mt.pdf)

Nederlands (NL) (606.3 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/nl/documents/product-information/rubraca-epar-product-information_nl.pdf)

norsk (NO) (635.93 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/no/documents/product-information/rubraca-epar-product-information_no.pdf)

polski (PL) (662.74 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/pl/documents/product-information/rubraca-epar-product-information_pl.pdf)

português (PT) (620.05 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/pt/documents/product-information/rubraca-epar-product-information_pt.pdf)

română (RO) (743.59 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/ro/documents/product-information/rubraca-epar-product-information_ro.pdf)

slovenčina (SK) (640.12 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/sk/documents/product-information/rubraca-epar-product-information_sk.pdf)

slovenščina (SL) (648.56 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/sl/documents/product-information/rubraca-epar-product-information_sl.pdf)

Suomi (FI) (582.91 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/fi/documents/product-information/rubraca-epar-product-information_fi.pdf)

svenska (SV) (580.63 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/sv/documents/product-information/rubraca-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000313308 27/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Rubraca : EPAR - All Authorised presentations

English (EN) (47.4 KB - PDF)

**First published:** 31/05/2018

**Last updated:** 27/11/2025

[View](/en/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-957)

български (BG) (65.24 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/bg/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_bg.pdf)

español (ES) (50.67 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/es/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_es.pdf)

čeština (CS) (59.51 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/cs/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (52.8 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/da/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (50.93 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/de/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (49.98 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/et/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (70.32 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/el/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_el.pdf)

français (FR) (47.08 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/fr/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (69.72 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/hr/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (50.53 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/is/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_is.pdf)

italiano (IT) (50.19 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/it/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (66.77 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/lv/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (65.75 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/lt/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (57.54 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/hu/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (63.99 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/mt/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (46.83 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/nl/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (49.92 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/no/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_no.pdf)

polski (PL) (59.29 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/pl/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_pl.pdf)

português (PT) (51.33 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/pt/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_pt.pdf)

română (RO) (57.75 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/ro/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (66.46 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/sk/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (65.5 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/sl/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (50.23 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/fi/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (48.36 KB - PDF)

**First published:**

31/05/2018

**Last updated:**

27/11/2025

[View](/sv/documents/all-authorised-presentations/rubraca-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Rubraca Active substance Rucaparib camsylate International non-proprietary name (INN) or common name rucaparib Therapeutic area (MeSH) Ovarian Neoplasms Anatomical therapeutic chemical (ATC) code L01XX

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.

Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

## Authorisation details

EMA product number EMEA/H/C/004272 Marketing authorisation holder

pharmaand GmbH

Taborstrasse 1

Opinion adopted 06/11/2017 Marketing authorisation issued 23/05/2018 Revision 18

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Rubraca : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (237.83 KB - PDF)

**First published:** 27/11/2025

[View](/en/documents/procedural-steps-after/rubraca-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Rubraca : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (171.95 KB - PDF)

**First published:** 19/12/2018

**Last updated:** 27/11/2025

[View](/en/documents/procedural-steps-after/rubraca-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Rubraca-H-C-4272-II-0036 : Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/503870/2023

English (EN) (7.33 MB - PDF)

**First published:** 30/11/2023

[View](/en/documents/variation-report/rubraca-h-c-4272-ii-0036-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Rubraca (II-36)

Adopted

Reference Number: EMA/CHMP/445199/2023

English (EN) (115.74 KB - PDF)

**First published:** 13/10/2023

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rubraca-ii-36_en.pdf)

Rubraca-H-C-4272-II-0029 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/883431/2022

English (EN) (14.42 MB - PDF)

**First published:** 25/11/2022

[View](/en/documents/variation-report/rubraca-h-c-4272-ii-0029-epar-assessment-report-variation_en.pdf)

Rubraca-H-A-20-1518-C-4272-0033 : Assessment report

Adopted

Reference Number: EMA/674344/2022

English (EN) (1.08 MB - PDF)

**First published:** 09/11/2022

[View](/en/documents/variation-report/rubraca-h-20-1518-c-4272-0033-assessment-report_en.pdf)

Rubraca : EPAR - Scientific conclusions Annex IV

English (EN) (734.52 KB - PDF)

**First published:** 09/11/2022

[View](/en/documents/scientific-conclusion/rubraca-epar-scientific-conclusions-annex-iv_en.pdf)

[Other languages (22)](#file-language-dropdown-659)

български (BG) (1.32 MB - PDF)

**First published:**

09/11/2022

[View](/bg/documents/scientific-conclusion/rubraca-epar-scientific-conclusions-annex-iv_bg.pdf)

español (ES) (725.5 KB - PDF)

**First published:**

09/11/2022

[View](/es/documents/scientific-conclusion/rubraca-epar-scientific-conclusions-annex-iv_es.pdf)

čeština (CS) (744.56 KB - PDF)

**First published:**

09/11/2022

[View](/cs/documents/scientific-conclusion/rubraca-epar-scientific-conclusions-annex-iv_cs.pdf)

dansk (DA) (714.84 KB - PDF)

**First published:**

09/11/2022

[View](/da/documents/scientific-conclusion/rubraca-epar-scientific-conclusions-annex-iv_da.pdf)

Deutsch (DE) (739.97 KB - PDF)

**First published:**

09/11/2022

[View](/de/documents/scientific-conclusion/rubraca-epar-scientific-conclusions-annex-iv_de.pdf)

eesti keel (ET) (711.82 KB - PDF)

**First published:**

09/11/2022

[View](/et/documents/scientific-conclusion/rubraca-epar-scientific-conclusions-annex-iv_et.pdf)

ελληνικά (EL) (737.75 KB - PDF)

**First published:**

09/11/2022

[View](/el/documents/scientific-conclusion/rubraca-epar-scientific-conclusions-annex-iv_el.pdf)

français (FR) (723.28 KB - PDF)

**First published:**

09/11/2022

[View](/fr/documents/scientific-conclusion/rubraca-epar-scientific-conclusions-annex-iv_fr.pdf)

hrvatski (HR) (758.94 KB - PDF)

**First published:**

09/11/2022

[View](/hr/documents/scientific-conclusion/rubraca-epar-scientific-conclusions-annex-iv_hr.pdf)

italiano (IT) (715.12 KB - PDF)

**First published:**

09/11/2022

[View](/it/documents/scientific-conclusion/rubraca-epar-scientific-conclusions-annex-iv_it.pdf)

latviešu valoda (LV) (756.77 KB - PDF)

**First published:**

09/11/2022

[View](/lv/documents/scientific-conclusion/rubraca-epar-scientific-conclusions-annex-iv_lv.pdf)

lietuvių kalba (LT) (756.49 KB - PDF)

**First published:**

09/11/2022

[View](/lt/documents/scientific-conclusion/rubraca-epar-scientific-conclusions-annex-iv_lt.pdf)

magyar (HU) (753.2 KB - PDF)

**First published:**

09/11/2022

[View](/hu/documents/scientific-conclusion/rubraca-epar-scientific-conclusions-annex-iv_hu.pdf)

Malti (MT) (772.31 KB - PDF)

**First published:**

09/11/2022

[View](/mt/documents/scientific-conclusion/rubraca-epar-scientific-conclusions-annex-iv_mt.pdf)

Nederlands (NL) (719.83 KB - PDF)

**First published:**

09/11/2022

[View](/nl/documents/scientific-conclusion/rubraca-epar-scientific-conclusions-annex-iv_nl.pdf)

polski (PL) (756.21 KB - PDF)

**First published:**

09/11/2022

[View](/pl/documents/scientific-conclusion/rubraca-epar-scientific-conclusions-annex-iv_pl.pdf)

português (PT) (727.02 KB - PDF)

**First published:**

09/11/2022

[View](/pt/documents/scientific-conclusion/rubraca-epar-scientific-conclusions-annex-iv_pt.pdf)

română (RO) (755.04 KB - PDF)

**First published:**

09/11/2022

[View](/ro/documents/scientific-conclusion/rubraca-epar-scientific-conclusions-annex-iv_ro.pdf)

slovenčina (SK) (738.97 KB - PDF)

**First published:**

09/11/2022

[View](/sk/documents/scientific-conclusion/rubraca-epar-scientific-conclusions-annex-iv_sk.pdf)

slovenščina (SL) (754.08 KB - PDF)

**First published:**

09/11/2022

[View](/sl/documents/scientific-conclusion/rubraca-epar-scientific-conclusions-annex-iv_sl.pdf)

Suomi (FI) (715.83 KB - PDF)

**First published:**

09/11/2022

[View](/fi/documents/scientific-conclusion/rubraca-epar-scientific-conclusions-annex-iv_fi.pdf)

svenska (SV) (728.75 KB - PDF)

**First published:**

09/11/2022

[View](/sv/documents/scientific-conclusion/rubraca-epar-scientific-conclusions-annex-iv_sv.pdf)

Rubraca-H-C-PSUSA-00010694-202012 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/526847/2021

English (EN) (161.7 KB - PDF)

**First published:** 20/09/2021

[View](/en/documents/scientific-conclusion/rubraca-h-c-psusa-00010694-202012-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Rubraca : Orphan designation withdrawal assessment report (post-authorisation)

Adopted

Reference Number: EMA/22653/2019

English (EN) (279.87 KB - PDF)

**First published:** 19/02/2019

[View](/en/documents/orphan-maintenance-report-post/rubraca-orphan-designation-withdrawal-assessment-report-post-authorisation_en.pdf)

Rubraca-H-C-4272-II-0001 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/902679/2019

English (EN) (5.56 MB - PDF)

**First published:** 19/02/2019

[View](/en/documents/variation-report/rubraca-h-c-4272-ii-0001-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Rubraca (II-01)

Adopted

Reference Number: EMA/CHMP/830894/2018

English (EN) (67.93 KB - PDF)

**First published:** 14/12/2018

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rubraca-ii-01_en.pdf)

## Initial marketing authorisation documents

Rubraca : Orphan designation withdrawal assessment report (initial authorisation)

Adopted

Reference Number: EMA/272157/2018

English (EN) (154.11 KB - PDF)

**First published:** 31/05/2018

**Last updated:** 31/05/2018

[View](/en/documents/orphan-maintenance-report/rubraca-orphan-designation-withdrawal-assessment-report-initial-authorisation_en.pdf)

Rubraca : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/238139/2018

English (EN) (5.97 MB - PDF)

**First published:** 31/05/2018

**Last updated:** 31/05/2018

[View](/en/documents/assessment-report/rubraca-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Rubraca

Adopted

Reference Number: EMA/CHMP/723380/2017

English (EN) (69.44 KB - PDF)

**First published:** 23/03/2018

**Last updated:** 23/03/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-rubraca_en.pdf)

#### News on Rubraca

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-october-2023) 13/10/2023

[EMA recommends restricting use of cancer medicine Rubraca](/en/news/ema-recommends-restricting-use-cancer-medicine-rubraca) 22/07/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018) 14/12/2018

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 March 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-march-2018) 23/03/2018

#### More information on Rubraca

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-12-1049) on 10 October 2012. Rubraca was withdrawn from the Community register of orphan medicinal products in November 2018 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

#### More information on Rubraca

- [EMEA-002760-PIP01-19 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002760-pip01-19)
- [Rubraca - referral](/en/medicines/human/referrals/rubraca)
- [Rubraca - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/rubraca-0)
- [Rubraca - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/rubraca)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 27/11/2025

## Share this page

[Back to top](#main-content)